PLT012是一种人性化的CD36阻断抗体,有效释放抗瘤免疫力,对抗肝癌和肝转移
Sheue-Fen Tzeng1,2, Yi-Ru Yu3,4,5, Jaeoh Park4,5
1Tumor Immune Analysis Core, Office of Research & Development, Taipei Medical University, Taipei, Taiwan.
Cancer discovery
|April 28, 2025
概括
代谢限制限制了癌症免疫治疗反应. PLT012通过向新陈代谢途径来恢复抗瘤免疫力,为改善肝细胞癌 (HCC) 免疫疗法提供了潜力.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 代谢途径 代谢途径
背景情况:
- 癌症免疫疗法,如免疫检查点抑制剂,显示出有希望但面临局限性.
- 瘤代谢限制是患者对免疫疗法的不响应的一个关键因素.
研究的目的:
- 研究PLT012在克服代谢限制方面的潜力.
- 评估PLT012在肝癌中恢复抗瘤免疫力的能力.
主要方法:
- 向瘤微环境中的特定代谢途径.
- 重新编程免疫系统,以增强抗瘤反应.
主要成果:
- PLT012证明了抗瘤免疫力的复苏.
- 在肝癌模型中成功重新编程免疫场景.
结论:
- PLT012显示了通过解决代谢瘤约束来增强免疫治疗疗效的潜力.
- 这种方法可能会显著影响未来的肝细胞癌 (HCC) 免疫治疗策略.
更多相关视频
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
8.7K
11:08Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
613
相关概念视频
01:27Tumor Immunotherapy
441
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
441
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K